Veterinary parasitology · 2020
One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Van Voorhis Wesley C, Hulverson Matthew A, Choi Ryan, Huang Wenlin, Arnold Samuel L M, Schaefer Deborah A, Betzer Dana P, Vidadala Rama S R, Lee Sangun, Whitman Grant R, Barrett Lynn K, Maly Dustin J, Riggs Michael W, Fan Erkang, Kennedy Thomas J, Tzipori Saul, Doggett J Stone, Winzer Pablo, Anghel Nicoleta, Imhof Dennis, Müller Joachim, Hemphill Andrew, Ferre Ignacio, Sanchez-Sanchez Roberto, Ortega-Mora Luis Miguel, Ojo Kayode K
Аннотация
This is a review of the development of bumped-kinase inhibitors (BKIs) for the therapy of One Health parasitic apicomplexan diseases. Many apicomplexan infections are shared between humans and livestock, such as cryptosporidiosis and toxoplasmosis, as well as livestock only diseases such as neosporosis. We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosporidium parvum), toxoplasmosis (pregnant sheep infected with Toxoplasma gondii), and neosporosis (pregnant sheep infected with Neospora caninum). We discuss the potential uses of BKIs for the treatment of diseases caused by apicomplexan parasites in animals and humans, and the improvements that need to be made to further develop BKIs.